Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nuclear paraspeckle assembly transcript 1 small interfering RNA
- Development stage
- Unknown
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Nuclear paraspeckle assembly transcript 1 small interfering RNA (NEAT1 siRNA) is a double-stranded RNA molecule designed to target and silence the long non-coding RNA (lncRNA) nuclear paraspeckle assembly transcript 1 (NEAT1). NEAT1 is a critical structural component of paraspeckles, which are subnuclear bodies involved in transcriptional regulation, mRNA retention, and cellular stress responses. In preclinical research, NEAT1 siRNA is utilized to investigate the role of NEAT1 in various pathological conditions, including neurodegenerative diseases like Alzheimer's disease and amyotrophic lateral sclerosis (ALS), as well as various cancers. Knockdown of NEAT1 using siRNA has been shown to reduce astrocyte reactivity, rescue memory deficits, and mitigate pathological protein aggregation in animal and cellular models.
- Other names
- NEAT1 siRNANEAT-1 siRNANEAT 1 siRNANeat1 small interfering RNANeat-1 small interfering RNANeat 1 small interfering RNAsi-NEAT1si-NEAT-1si-NEAT 1
02
Targets
NEAT1 (Nuclear paraspeckle assembly transcript 1)
Beyond the preview
Go deeper on nuclear paraspeckle assembly transcript 1 small interfering RNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nuclear paraspeckle assembly transcript 1 small interfering RNA.